Cannabinoid–Opioid Cross-Tolerance Was One-Way in a Mouse Formalin Study
Prior morphine reduced the later response to JWH-133, while prior JWH-133 did not produce the corresponding reduction in morphine response. Cross-tolerance need not be reciprocal.
The model involved inflammatory behavior
Male and female mice underwent formalin testing with JWH-133, a selective experimental CB2 agonist. Researchers evaluated repeated treatment, prior drug histories and combinations with morphine. The compound was not THC or a cannabis extract.
Sequence and interaction type were separate
The observed cross-tolerance ran from morphine history to JWH-133 response, not in both directions. Formal combination analysis supported additive antinociception rather than a demonstrated synergistic effect. Those distinctions matter even when both drugs show activity individually.
What cannot be generalized
The reported lack of JWH-133 tolerance during the studied regimen does not prove indefinite efficacy. Female baseline pain behavior also complicated simple comparisons of raw behavioral totals. These animal findings cannot establish that cannabis prevents opioid tolerance or that prior opioid exposure predicts an individual’s THC response. They show why a cross-tolerance statement must identify the initial drug, challenge drug, endpoint and direction rather than treating the relationship as symmetric.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Molecular pain (2017). DOI: 10.1177/1744806917728227.
